Cashu | Summary

DJI

+0.52%

SPX

+0.53%

IXIC

+0.52%

FTSE

-0.86%

N225

-1.44%

AXJO

-0.81%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

HomeWatchlistNewsSignalsPicks

DJI

+0.52%

SPX

+0.53%

IXIC

+0.52%

FTSE

-0.86%

N225

-1.44%

AXJO

-0.81%

HomeWatchlistNewsSignalsPicks

Join our newsletter to keep up to date with us!

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap

2.42B

Dividend Yield

0.00%

P/E Ratio

-5.05

EPS

-2.58

Revenue

Avg. Volume

1.90M

About

What does DNLI do?

Denali Therapeutics, a biopharmaceutical company based in South San Francisco, develops therapies for neurodegenerative diseases, with seven clinical candidates and ongoing studies for conditions like ALS and Parkinson's disease. The company went public on December 8, 2017, and has 375 employees.

Sector

💻 Health Care

IPO

CEO

Employees

486

Headquarters

California, USA

Website

http://www.denalitherapeutics.com